[{"orgOrder":0,"company":"Mannin Research","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Undisclosed","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Mannin Research","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Mannin Research \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Mannin Research \/ Not Applicable"},{"orgOrder":0,"company":"Mannin Research","sponsor":"Q BioMed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"MAN-19","moa":"Tie2","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Mannin Research","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Mannin Research \/ Mannin Research Inc","highestDevelopmentStatusID":"4","companyTruncated":"Mannin Research \/ Mannin Research Inc"},{"orgOrder":0,"company":"Mannin Research","sponsor":"Q BioMed","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"MAN-01","moa":"IOP","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Mannin Research","amount2":0.040000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0.040000000000000001,"dosageForm":"Solution\/Drops","sponsorNew":"Mannin Research \/ Mannin Research","highestDevelopmentStatusID":"4","companyTruncated":"Mannin Research \/ Mannin Research"}]

Find Clinical Drug Pipeline Developments & Deals by Mannin Research

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : By utilizing MRI’s internal pro-forma revenue projections for 2023 & 2024 and comparable market transactions, MRI’s drug development pipeline including MAN-01 and companion diagnostics, are estimated to achieve a net present value.

                          Brand Name : MAN-01

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          November 14, 2022

                          Lead Product(s) : MAN-01

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Preclinical

                          Recipient : Q BioMed

                          Deal Size : $42.3 million

                          Deal Type : Agreement

                          blank

                          02

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : MAN-19 therapeutic is a recombinant fusion protein that treats the patient, instead of targeting the virus. It is not a cure for COVID, but it strengthens a patient's blood vessels and protects them against ARDS, breathing problems, sepsis and other infe...

                          Brand Name : MAN-19

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          September 22, 2021

                          Lead Product(s) : MAN-19

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Recipient : Q BioMed

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Platform has been awarded grants from Canada and Europe for its development of therapeutics; additional grant submitted to the STTR program administered by the U.S. National Institutes of Health.

                          Brand Name : Undisclosed

                          Molecule Type : Undisclosed

                          Upfront Cash : Not Applicable

                          February 20, 2020

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank